Advertisement

Increased 1-year continuation of DMPA among women randomized to self-administration: results from a randomized controlled trial at Planned Parenthood

      Abstract

      Objectives

      Self-administration of subcutaneous depot medroxyprogesterone acetate (DMPA-sc) is feasible, acceptable, and effective. Our objective was to compare one-year continuation of DMPA-sc between women randomized to self-administration versus clinic administration.

      Study design

      We randomized 401 females ages 15–44 requesting DMPA at clinics in Texas and New Jersey to self-administration or clinic administration in a 1:1 allocation. Clinic staff taught participants randomized to self-administration to self-inject and observed the first injection; participants received instructions, a sharps container, and three doses for home use. Participants randomized to clinic administration received usual care. All participants received DMPA-sc at no cost and injection reminders via text message or email. We conducted follow-up surveys at six and 12 months.

      Results

      Three hundred thirty-six participants (84%) completed the 12-month survey; 316 completed both follow-up surveys (an 80% response rate excluding eight withdrawals). Participants ranged in age from 16–44. One-year DMPA continuous use was 69% in the self-administration group and 54% in the clinic group (p=.005). There were three self-reported pregnancies during the study period, all occurred in the clinic group; all three women had discontinued DMPA and one reported her pregnancy as intended.
      Among the self-administration group, 97% reported that self-administration was very or somewhat easy; 87% would recommend self-administration of DMPA-sc to a friend. Among the clinic group, 52% reported interest in self-administration in the future. Satisfaction was similar between groups. No serious adverse events were reported.

      Conclusions

      DMPA self-administration improves contraceptive continuation and is a feasible and acceptable option for women and adolescents.

      Implications

      Self-administration of subcutaneous DMPA can improve contraceptive access, autonomy, and continuation, and is a feasible and acceptable option for women and adolescents. It should be made widely available as an option for women and adolescents.

      Abbreviations:

      DMPA (depot medroxyprogesterone acetate), DMPA-IM (intramuscular depot medroxyprogesterone acetate), DMPA-sc (subcutaneous depot medroxyprogesterone acetate)

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Contraception
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • U.S. Department of Health and Human Services Office of Disease Prevention and Health Promotion
        Healthy people 2020.
        http://www.healthypeople.gov/2020/about/default.aspx
        Date: 2013
        Date accessed: November 17, 2013
        • Finer L.B.
        • Zolna M.R.
        Declines in unintended pregnancy in the United States, 2008–2011.
        N Engl J Med. 2016; 374: 843-852https://doi.org/10.1056/NEJMsa1506575
        • Lindberg L.
        • Santelli J.
        • Desai S.
        Understanding the decline in adolescent fertility in the United States, 2007–2012.
        J Adolesc Health. 2016; 59: 577-583https://doi.org/10.1016/j.jadohealth.2016.06.024
        • Guttmacher Institute
        Contraceptive use in the United States.
        • Planned Parenthood Federation of America (PPFA)
        2015–2016 Annual Report.
        • Jain J.
        • Jakimiuk A.J.
        • Bode F.R.
        • Ross D.
        • Kaunitz A.M.
        Contraceptive efficacy and safety of DMPA-SC.
        Contraception. 2004; 70: 269-275https://doi.org/10.1016/j.contraception.2004.06.011
        • Beasley A.
        • White K.O.
        • Cremers S.
        • Westhoff C.
        Randomized clinical trial of self versus clinical administration of subcutaneous depot medroxyprogesterone acetate.
        Contraception. 2014; 89: 352-356https://doi.org/10.1016/j.contraception.2014.01.026
        • Prabhakaran S.
        • Sweet A.
        Self-administration of subcutaneous depot medroxyprogesterone acetate for contraception: feasibility and acceptability.
        Contraception. 2012; 85: 453-457https://doi.org/10.1016/j.contraception.2011.09.015
        • Williams R.L.
        • Hensel D.J.
        • Fortenberry D.
        Self-administration of subcutaneous depot medroxyprogesterone acetate by adolescent women.
        Contraception. 2013; 88: 401-407https://doi.org/10.1016/j.contraception.2012.11.019
        • Cameron S.T.
        • Glasier A.
        • Johnstone A.
        Pilot study of home self-administration of subcutaneous depo-medroxyprogesterone acetate for contraception.
        Contraception. 2012; 85: 458-464https://doi.org/10.1016/j.contraception.2011.10.002
        • Lakha F.
        • Henderson C.
        • Glasier A.
        The acceptability of self-administration of subcutaneous depo-provera.
        Contraception. 2005; 72: 14-18https://doi.org/10.1016/j.contraception.2004.12.002
        • Stanwood N.L.
        • Eastwood K.
        • Carletta A.
        Self-injection of monthly combined hormonal contraceptive.
        Contraception. 2006; 73: 53-55https://doi.org/10.1016/j.contraception.2005.05.020
        • Upadhyay U.D.
        • Zlidar V.M.
        • Foster D.G.
        Interest in self-administration of subcutaneous depot medroxyprogesterone acetate in the United States.
        Contraception. 2016; 94: 303-313https://doi.org/10.1016/j.contraception.2016.06.006
        • Keith B.
        • Wood S.
        • Tifft S.
        • Hutchings J.
        Home-based administration of Sayana® press: review and assessment of needs in low-resource settings.
        Contraception. 2014; 89: 344-351https://doi.org/10.1016/j.contraception.2014.03.003
        • Burke H.M.
        • Mueller M.P.
        • Perry B.
        • Packer C.
        • Bufumbo L.
        • Mbengue D.
        • et al.
        Observational study of the acceptability of Sayana® press among intramuscular DMPA users in Uganda and Senegal.
        Contraception. 2014; 89: 361-367https://doi.org/10.1016/j.contraception.2014.01.022
        • Curtis K.M.
        • Tepper N.K.
        • Jatlaoui T.C.
        • Berry-Bibee E.
        • Horton L.G.
        • Zapata L.B.
        • et al.
        U.S. medical eligibility criteria for contraceptive use, 2016.
        MMWR Recomm Rep. 2016; 65: 1-104https://doi.org/10.15585/mmwr.rr6503a1
        • Rickert V.I.
        • Tiezzi L.
        • Lipshutz J.
        • León J.
        • Vaughan R.D.
        • Westhoff C.
        Depo now: preventing unintended pregnancies among adolescents and young adults.
        J Adolesc Health. 2007; 40: 22-28https://doi.org/10.1016/j.jadohealth.2006.10.018
        • Secura G.M.
        • Allsworth J.E.
        • Madden T.
        • Mullersman J.L.
        • Peipert J.F.
        The contraceptive CHOICE project: reducing barriers to long-acting reversible contraception.
        Am J ObstetGynecol. 2010; 203: 115.e1-115.e7https://doi.org/10.1016/j.ajog.2010.04.017
        • Trussell J.
        Contraceptive failure in the United States.
        Contraception. 2011; 83: 397-404https://doi.org/10.1016/j.contraception.2011.01.021
        • Raine T.R.
        • Foster-Rosales A.
        • Upadhyay U.D.
        • Boyer C.B.
        • Brown B.A.
        • Sokoloff A.
        • et al.
        One-year contraceptive continuation and pregnancy in adolescent girls and women initiating hormonal contraceptives.
        Obstet Gynecol. 2011; 117: 363-371https://doi.org/10.1097/AOG.0b013e31820563d3